Abbott, the global healthcare company, has received a partial victory in a suit against Novartis, the Swiss multinational pharmaceutical company. The lawsuit sought clarification whether Abbott had infringed Novartis’s patent involving a DNA replication method, alleged to have been utilised in Abbott’s HIV test.
An Illinois federal judge has determined that parts of the Novartis patent were valid, however, Abbott’s actions did not infrwhich on the patent. This decision delivers a significant legal reprieve for Abbott in the increasingly competitive and legally complex field of pharmaceutical patents.
For further in-depth information, you may refer to the original article on Law360.